Hard to Treat Diseases HTDS Stock
Hard to Treat Diseases Price Chart
Hard to Treat Diseases HTDS Financial and Trading Overview
| Hard to Treat Diseases stock price | 0.0000 USD |
| Previous Close | 2.0E-5 USD |
| Open | 1.0E-6 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 1.0E-6 - 1.0E-6 USD |
| 52 Week Range | 1.0E-6 - 2.0E-5 USD |
| Volume | 1 USD |
| Avg. Volume | 0 USD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.697 |
| PE Ratio (TTM) | |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
HTDS Valuation Measures
| Enterprise Value | 254.37K USD |
| Trailing P/E | |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 0.041 |
| Enterprise Value/EBITDA | 0.248 |
Trading Information
Hard to Treat Diseases Stock Price History
| Beta (5Y Monthly) | 0.697 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 2.0E-5 USD |
| 52 Week Low | 1.0E-6 USD |
| 50-Day Moving Average | 2.0E-5 USD |
| 200-Day Moving Average | 2.0E-5 USD |
HTDS Share Statistics
| Avg. Volume (3 month) | 0 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 5.48B |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2009 |
| Most Recent Quarter (mrq) | September 30, 2010 |
| Next Fiscal Year End | December 31, 2010 |
Profitability
| Profit Margin | 15.82% |
| Operating Margin (ttm) | 17.26% |
| Gross Margin | 28.94% |
| EBITDA Margin | 16.64% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 6.16M USD |
| Revenue Per Share (ttm) | 0.001 USD |
| Quarterly Revenue Growth (yoy) | 5.70% |
| Gross Profit (ttm) | 1.78M USD |
| EBITDA | 1.03M USD |
| Net Income Avi to Common (ttm) | 974.3K USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 202.9K USD |
| Total Cash Per Share (mrq) | 0 USD |
| Total Debt (mrq) | 450.45K USD |
| Total Debt/Equity (mrq) | 20.63 USD |
| Current Ratio (mrq) | 2.265 |
| Book Value Per Share (mrq) | 0 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.03M USD |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Hard to Treat Diseases
| Country | United States |
| State | FL |
| City | Clearwater |
| Address | 2655 Ulmerton Road |
| ZIP | 33762 |
| Phone | N/A |
| Website | N/A |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Hard to Treat Diseases Inc. manufactures, supplies, and exports human vaccines and biological products in China and internationally. The company offers human vaccines, such as recombinant human papillomavirus bivalent, freeze-dried live attenuated hepatitis A, recombinant hepatitis E, meningococcal polysaccharide, 23-valent pneumococcal polysaccharide, varicella, rabies, group ACYW135meningococcal conjugate, inactivated poliomyelitis, enterovirus Type 71, influenza, meningococcal Group A, C bivalent polysaccharide conjugate, recombinant hepatitis B, poliomyelitis, and pneumococcal polysaccharide conjugate vaccines. It also provides biopharmaceuticals, including recombinant human coagulation factor VIII for injection, insulin aspart injection, cerebroprotein hydrolysate for injection, recombinant human basic fibroblast growth factor, insulin glargine injection, mouse nerve growth factor for injection, trastuzumab injection, bevacizumab injection, adalimumab injection, recombinant human epidermal growth factor eye drop, recombinant human interferon a2b injection, reteplase (rPA ), and levonorgestrel silastic implant products. In addition, the company offers plasma products comprises human coagulation factor IV, human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, and human immunoglobulin (pH4) for intravenous injection; and chemicals that consists of olaparib tablets, enzalutamide soft capsules, and eribulin mesilate injection. The company markets its products through distribution and sales network. Hard to Treat Diseases Inc. is based in Clearwater, Florida.
Q&A For Hard to Treat Diseases Stock
What is a current HTDS stock price?
Hard to Treat Diseases HTDS stock price today per share is 0.0000 USD.
How to purchase Hard to Treat Diseases stock?
You can buy HTDS shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Hard to Treat Diseases?
The stock symbol or ticker of Hard to Treat Diseases is HTDS.
Which industry does the Hard to Treat Diseases company belong to?
The Hard to Treat Diseases industry is Biotechnology.
How many shares does Hard to Treat Diseases have in circulation?
The max supply of Hard to Treat Diseases shares is 0.
What is Hard to Treat Diseases Price to Earnings Ratio (PE Ratio)?
Hard to Treat Diseases PE Ratio is now.
What was Hard to Treat Diseases earnings per share over the trailing 12 months (TTM)?
Hard to Treat Diseases EPS is 0 USD over the trailing 12 months.
Which sector does the Hard to Treat Diseases company belong to?
The Hard to Treat Diseases sector is Healthcare.